Company profile
Indo Global Exchange(s) PTE, Ltd.
OTC: IGEX · Healthcare · Drug Manufacturers - Specialty & Generic
PublicHQ Jakarta, CIK 0001442853Reports USD
#1161 of 1,418 Healthcare companies by revenuebottom-decile growth
EA Score
——FH —DQ 8GM —SS 48
v0.1 · 25/100 weight · pillars only
↑ Altman-Z, listing tenure · ↓ revenue growth (YoY), 3-yr revenue growth
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
$0
Employees
—
as of 2026-07-19
Market cap
$2.6M
as of 2026-07-19
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02017
Net income$0$02017
Total assets$0$02017
Liabilities$486.5k$486.5k2017
Equity-$486.5k-$486.5k2017
Revenue trend
FY2015 – FY2017 · USD
FY15
FY16
FY16
FY17
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Indo Global Exchange(s) PTE, Ltd.’s revenue?
Indo Global Exchange(s) PTE, Ltd. booked $0 in FY2017 revenue, contracting 100% year over year — among the slowest-growing Healthcare companies we track, at a NaN% net margin.
Peers · Healthcare
Medican Enterprises, Inc.——Autonomix Medical, Inc.28DEco-Growth Strategies Inc.——BioVaxys Technology Corp.——VitaSpring Biomedical Co. Ltd.18DPsyence Group Inc.——Key facts
CEOSergio Bellosta Suarez
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersJakarta, null
ExchangeOTC: IGEX
Employees—
IPO date2013-05-29
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.